Advertisement

Hypoglycemia

  • Christian Meyer
  • Steven D. Wittlin
  • John E. Gerich

Abstract

As indicated earlier in the chapter on Normal Glucose Homeostasis, human plasma glucose concentrations are maintained within a relatively narrow range throughout the day (usually between 55 and 165 mg/dl, ~3.0 and 9.0 mM) despite wide fluctuations in the delivery (e.g. meals) and removal (e.g. exercise) of glucose from the circulation. This is accomplished by a tightly linked balance between glucose production and glucose utilization regulated by complex mechanisms.

Keywords

Islet Transplantation Intensive Insulin Therapy Insulin Lispro Continuous Subcutaneous Insulin Infusion Pancreas Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Owen O, Morgan A, Kemp H, Sullivan J, Herrera M, Cahill G. Brain metabolism during fasting. J Clin Invest 46: 1589–1595, 1967.PubMedCrossRefGoogle Scholar
  2. 2.
    Cryer P. Banting Lecture: Hypoglycemia, the limiting factor in the management of IDDM. Diabetes 43: 1378–1389, 1994.PubMedCrossRefGoogle Scholar
  3. 3.
    Cryer P, Binder C, Bolli G, Cherrington A, Gale E, Gerich J, Sherwin R. Hypoglycemia in IDDM. Diabetes 38: 1193–1199, 1989.PubMedCrossRefGoogle Scholar
  4. 4.
    Foster D, Rubenstein A. Hypoglycemia. In: Wilson J, Braunwald E, Isselbacher K: Harrison’s Principles of internal medicine, New York McGraw-Hill, 1759, 1991.Google Scholar
  5. 5.
    DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. NEngl J Med 329: 977–986, 1993.Google Scholar
  6. 6.
    Egger M, Smith GD, Stettler C, Diem P. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: ametaanalysis. Diabet Med 14: 919–928, 1997.PubMedCrossRefGoogle Scholar
  7. 7.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853, 1998.Google Scholar
  8. 8.
    Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furugoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103–117, 1995.PubMedCrossRefGoogle Scholar
  9. 9.
    Hepburn D, MacLeod K, Pell A, Scougal I, Frier B. Frequency and Symptoms of hypoglycemia experienced by patients with type 2 diabetes treated with insulin. Diab Med 10: 231–237, 1993.CrossRefGoogle Scholar
  10. 10.
    Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 50: 735–741, 1997.PubMedCrossRefGoogle Scholar
  11. 11.
    Gerich J. Sulfonylureas in the treatment of diabetes mellitus. Mayo Clin Proc 60: 439–443, 1985.PubMedCrossRefGoogle Scholar
  12. 12.
    DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am JMed 90: 450–459, 1991.Google Scholar
  13. 13.
    Nilsson A, Tideholm B, Kalen J, Katzman P. Incidence of severe hypoglycemia and its causes in insulin-treated diabetics. Acta Med Scand 224: 257–262, 1988.PubMedCrossRefGoogle Scholar
  14. 14.
    Amiel S. R.D. Lawrence Lecture 1994. Limits of normality: the mechanisms of hypoglycemia unawareness. Diabetic Med 11: 918–924, 1994.PubMedCrossRefGoogle Scholar
  15. 15.
    Mokan M, Mitrakou M, Veneman T, Ryan C, Korytkowski M, Cryer P, Gerich J. Hypoglycemia unawareness in IDDM. Diabetes Care 17: 1397–1403, 1994.PubMedCrossRefGoogle Scholar
  16. 16.
    Bolli G, DeFeo P, Compagnucci P, Cartechini M, Angeletti G, Santeusanio F, Brunetti P, Gerich J. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus: interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 32: 134–141, 1983.PubMedCrossRefGoogle Scholar
  17. 17.
    Amiel S, Tamborlane W, Simonson D, Sherwin R. Defective glucose counterregulation after strict control of insulin-dependent diabetes mellitus. N Engl J Med 316: 1376–1383, 1987.PubMedCrossRefGoogle Scholar
  18. 18.
    Simonson D, Tamborlane W, DeFronzo R, Sherwin R. Intensive insulin therapy reduces counterregulatory responses to hypoglycemia in type I diabetes. Ann Int Med 103: 184–188, 1985.PubMedCrossRefGoogle Scholar
  19. 19.
    Davis M, Mellman M, Shamoon H. Further defects in counterregulatory responses induced by recurrent hypoglycemia in IDDM. Diabetes 41: 1335–1340, 1992.PubMedCrossRefGoogle Scholar
  20. 20.
    Lingenfelser T, Renn W, Sommerwerck U, Buettner U, ZaiserKaschel H, Kaschel R, Eggstein M, Jakober B. Compromised hormonal counterregulation, symptom awareness, and neurophysiologie function after recurrent short-term episodes of insulin-induced hypoglycemia in IDDM patients. Diabetes 42: 610–618, 1993.PubMedCrossRefGoogle Scholar
  21. 21.
    Meyer C, Großmann R, Mitrakou A, Mahler R, Veneman T, Gerich J, Bretzel R. Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients. Diabetes Care 21: 1960–1966, 1998.PubMedCrossRefGoogle Scholar
  22. 22.
    Horie H, Hanafusa T, Matsuyama T, Namba M, Nonaka K, Tarui S, Yamatodani A, Wada H. Decreased response of epinephrine and norepinephrine to insulin-induced hypoglycemia in diabetic autonomic neuropathy. Horm Metab Res 16: 398–401, 1984.PubMedCrossRefGoogle Scholar
  23. 23.
    Hoeldtke R, Boden G, Shuman C, Owen C. Reduced epinephrine secretion and hypoglycemic unawareness in diabetic autonomic neuropathy. Ann Int Med 96: 459–462, 1982.PubMedCrossRefGoogle Scholar
  24. 24.
    Hirsch I, Boyle P, Craft S, Cryer P. Higher glycemic thresholds for symptoms during b-adrenergic blockade in IDDM. Diabetes 40: 1177–1186, 1991.PubMedCrossRefGoogle Scholar
  25. 25.
    White N, Skor D, Cryer P, Bier D, Levandoski L, Santiago J. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 308: 485491, 1983.Google Scholar
  26. 26.
    Gold A, MacLeod K, Frier B. Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. Diabetes Care 17: 697–703, 1994.PubMedCrossRefGoogle Scholar
  27. 27.
    Gerich J. Hypoglycemia. In: DeGroot L. Endocrinology, 4 edn., Philadelphia, W. B. Saunders, 2001, 921.Google Scholar
  28. 28.
    Gerich J. Glucose counterregulation and its impact on diabetes mellitus. Diabetes 37: 1608–1617, 1988.PubMedCrossRefGoogle Scholar
  29. 29.
    Bolli G, Dimitriadis G, Pehling G, Baker B, Haymond M, Cryer P, Gerich J. Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus. N Engl J Med 310: 1706–1711, 1984.PubMedCrossRefGoogle Scholar
  30. 30.
    Cersosimo E, Garlick P, Ferretti J. Renal glucose production during insulin-induced hypoglycemia in humans. Diabetes 48: 261–266, 1999.PubMedCrossRefGoogle Scholar
  31. 31.
    Meyer C, Dostou J, Gerich J. Role of the human kidney in glucose counterregulation. Diabetes 48: 943–948, 1999.PubMedCrossRefGoogle Scholar
  32. 32.
    Schwartz N, Clutter W, Shah S, Cryer P. The glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 79: 777–781, 1987.PubMedCrossRefGoogle Scholar
  33. 33.
    Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I, Durrant J, Cryer P, Gerich J. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 260: E67 - E74, 1991.PubMedGoogle Scholar
  34. 34.
    Fanelli C, Pampanelli S, Epifano L, Rambotti A, Ciofetta M, Modarelli F, DiVincenzo A, Annibale B, Lepore M, Lalli C, DelSindaco P, Brunetti P, Bolli G. Relative roles of insulin and hypoglycemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycemia in male and female humans. Diabetologia 37: 797–807, 1994.PubMedCrossRefGoogle Scholar
  35. 35.
    DeFeo P, Perriello G, Torlone E, Ventura M, Santeusanio F, Brunetti P, Gerich J, Bolli G. Demonstration of a role of growth hormone in glucose counterregulation. Am J Physiol 256: E835 - E843, 1989.Google Scholar
  36. 36.
    DeFeo P, Perriello G, Torlone E, Ventura M, Fanelli C, Santeusanio F, Brunetti P, Gerich J, Bolli G. Contribution of cortisol to glucose counterregulation in man. Am J Physiol 257: E35 - E42, 1989.Google Scholar
  37. 37.
    Lecavalier L, Bolli G, Cryer P, Gerich J. Contributions of gluconeogenesis and glycogenolysis during glucose counterregulation in normal humans. Am J Physiol 256: E844 - E851, 1989.PubMedGoogle Scholar
  38. 38.
    Stumvoll M, Meyer C, Kreider M, Perriello G, Gerich J. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Metabolism 47: 1227–1232, 1998.PubMedCrossRefGoogle Scholar
  39. 39.
    Stumvoll M, Meyer C, Perriello G, Kreider M, Welle S, Gerich J. Human kidney and liver gluconeogenesis: evidence for organ substrate selectivity. Am J Physiol 274: E817 - E826, 1998.PubMedGoogle Scholar
  40. 40.
    Meyer C, Stumvoll M, Welle S, Nair S, Haymond M, Gerich J. Sites, substrates and mechanisms of epinephrine stimulated glucose production in humans. Diabetes 47(Suppl 1):A305, 1998(Abstract).Google Scholar
  41. 41.
    Rizza R, Haymond M, Cryer P, Gerich J. Differential effects of physiologic concentrations of epinephrine on glucose production and disposal in man. Am J Physiol 237: 356–362, 1979.Google Scholar
  42. 42.
    Sacca L, Morrone G, Cicala M, Corso G, Ungaro B. Influence of epinephrine, norepinephrine and isoproterenol on glucose homeostasis in normal man. J Clin Endocrinol Metab 50: 680–684, 1980.PubMedCrossRefGoogle Scholar
  43. 43.
    Sacca L, Vigorito C, Cicala M, Corso G, Sherwin R. Role of gluconeogenesis in epinephrine-stimulated hepatic glucose production in humans. Am J Physiol 245: E294 - E302, 1983.PubMedGoogle Scholar
  44. 44.
    Clutter W, Bier D, Shah S, Cryer P. Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. J Clin Invest 66: 94–101, 1980.PubMedCrossRefGoogle Scholar
  45. 45.
    Gerich J, Campbell P. Overview of counterregulation and its abnormalities in diabetes mellitus and other conditions. Diabetes Metab Rev 4: 93–111, 1988.PubMedCrossRefGoogle Scholar
  46. 46.
    McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 4: 17–30, 1988.PubMedCrossRefGoogle Scholar
  47. 47.
    Hepburn D, Deary I, Frier B, Patrick A, Quinn J, Fisher B. Symptoms of acute insulin-induced hypoglycemia in humans with and without IDDM. Factor-analysis approach. Diabetes Care 14: 949–957, 1991.PubMedCrossRefGoogle Scholar
  48. 48.
    Towler D, Havlin C, Craft S, Cryer P. Mechanism of awareness of hypoglycemia: perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 42: 1791–1798, 1993.PubMedCrossRefGoogle Scholar
  49. 49.
    Cox D, Gonder-Frederick L, Antoun B, Cryer P, Clarke W. Perceived symptoms in the recognition of hypoglycemia. Diabetes Care 16: 519–527, 1993.PubMedCrossRefGoogle Scholar
  50. 50.
    Bolli G, DeFeo P, Perriello G, DeCosmo S, Ventura M, Campbell P, Brunetti P, Gerich J. Role of hepatic autoregulation in defense against hypoglycemia in humans. J Clin Invest 75: 1623–1631, 1985.PubMedCrossRefGoogle Scholar
  51. 51.
    Mitrakou A, Fanelli C, Veneman T, Perriello G, Calderone S, Plantanisiotis D, Rambotti A, Raptis S, Brunetti P, Cryer P, Gerich J, Bolli G. Reversibility of unawareness of hypoglycemia in patients with insulinomas. N Engl J Med 329: 834–839, 1993.PubMedCrossRefGoogle Scholar
  52. 52.
    Heller S, Cryer P. Hypoinsulinemia is not critical to glucose recovery from hypoglycemia in humans. Am J Physiol 261: E41 - E48, 1991.PubMedGoogle Scholar
  53. 53.
    DeFeo P, Perriello G, DeCosmo S, Ventura M, Campbell P, Brunetti P, Gerich J, Bolli G. Comparison of glucose counterregulation during short-term and prolonged hypoglycemia in normal humans. Diabetes 35: 563–569, 1986.CrossRefGoogle Scholar
  54. 54.
    Sacca L, Sherwin R, Hendler R, Felig P. Influence of continuous physiologic hyperinsulinemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans. J Clin Invest 63: 849–857, 1979.PubMedCrossRefGoogle Scholar
  55. 55.
    DeFeo P, Perriello G, Ventura M, Brunetti P, Santeusanio F, Gerich J, Bolli G. The pancreatic-adrenocortical-pituitary clamp technique for study of counterregulation in humans. Am J Physiol 252: E565 - E570, 1987.Google Scholar
  56. 56.
    DeFeo P, Perriello G, Torlone E, Fanelli C, Ventura M, Santeussanio F, Brunetti P, Gerich J, Bolli G. Contribution of adrenergic mechanisms to glucose counterregulation in humans. Am J Physiol 261: E725 - E736, 1991.Google Scholar
  57. 57.
    Gerich J, Langlois M, Noacco C, Karam J, Forsham P. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha-cell defect. Science 182: 171–173, 1973.PubMedCrossRefGoogle Scholar
  58. 58.
    Fukuda M, Tanaka A, Tahara Y, Ikegami H, Yamamoto Y, Kumahara Y, Shima K. Correlation between minimal secretory capacity of pancreatic ß-cells and stability of diabetic control. Diabetes 37: 81–88, 1988.PubMedCrossRefGoogle Scholar
  59. 59.
    Rizza R, Cryer P, Gerich J. Role of glucagon, epinephrine and growth hormone in glucose counterregulation. J Clin Invest 64: 62–71, 1979.PubMedCrossRefGoogle Scholar
  60. 60.
    Hirsch B, Shamoon H. Defective epinephrine and growth hormone responses in type I diabetes are stimulus specific. Diabetes 36: 20–26, 1987.PubMedCrossRefGoogle Scholar
  61. 61.
    Dagogo-Jack S, Craft S, Cryer P. Hypoglycemia-associated autonomic failure in insulin dependent diabetes mellitus. J Clin Invest 91: 819–828, 1993.PubMedCrossRefGoogle Scholar
  62. 62.
    Bolli G, DeFeo P, DeCosmo S, Perriello G, Ventura M, Benedetti M, Santeusanio F, Gerich J, Brunetti P. A reliable and reproducible test for adequate glucose counterregulation in Type I diabetes mellitus. Diabetes 33: 732–737, 1984.PubMedCrossRefGoogle Scholar
  63. 63.
    Cersosimo E, Ferretti J, Sasvary D, Garlick P. Adrenergic stimulation of renal glucose release is impaired in type 1 diabetes. Diabetes 50 (Suppl 2): A54, 2001.Google Scholar
  64. 64.
    Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic hypoglycemia in 411 type I diabetic patients. Diabetic Med 8: 217–222, 1991.PubMedCrossRefGoogle Scholar
  65. 65.
    Hepburn D, Patrick A, Eadington D, Ewing D, Frier B. Unawareness of hypoglycemia in insulin-treated diabetic patients: prevalence and relationship to autonomic neuropathy. Diabetic Med 7: 711–717, 1990.PubMedCrossRefGoogle Scholar
  66. 66.
    Unger R. Insulin-glucagon relationships in the defense against hypoglycemia. Diabetes 32: 575–583, 1983.PubMedGoogle Scholar
  67. 67.
    Boyle P, Kempers S, O’Connor A, Nagy R. Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus. N Engl J Med 333: 1726–1731, 1995.PubMedCrossRefGoogle Scholar
  68. 68.
    Fritsche A, Stumvoll M, Grab M, Sieslack S, Renn W, Schmülling R-M, Häring H-U, Gerich J. Effect of hypoglycemia on badrenergic sensitivity in normal and type 1 diabetic subjects. Diabetes Care 21: 1505–1510, 1998.PubMedCrossRefGoogle Scholar
  69. 69.
    Heller S, MacDonald I, Tattersall R. Counterregulation in type 2 (noninsulin-dependent) diabetes mellitus: normal endocrine and glycemic responses, up to 10 years after diagnosis. Diabetologia 30: 924–929, 1987.PubMedCrossRefGoogle Scholar
  70. 70.
    Levy C, Kinsley B, Bajaj M, Simonson D. Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Diabetes Care 21: 1330–1338, 1998.PubMedCrossRefGoogle Scholar
  71. 71.
    Shamoon H, Friedman S, Canton C, Zacharowicz L, Hu M, Rossetti L. Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus. J Clin Invest 93: 2562–2571, 1994.PubMedCrossRefGoogle Scholar
  72. 72.
    Segel S, Paramore D, Cryer P. Defective glucose counterregulation in type 2 diabetes. Diabetes 49 (Suppl 1): A131, 2000 (Abstract).CrossRefGoogle Scholar
  73. 73.
    Bolli G, Tsalikian E, Haymond M, Cryer P, Gerich J. Defective glucose counterregulation after subcutaneous insulin in noninsulindependent diabetes mellitus. J Clin Invest 73: 1532–1541, 1984.PubMedCrossRefGoogle Scholar
  74. 74.
    Woerle HJ, Meyer C, Popa E, Cryer P, Gerich J. Renal compensation for impaired hepatic glucose release during hypoglycemia in type 2 diabetes. Diabetologia (In Press).Google Scholar
  75. 75.
    Magnusson I, Rothman D, Katz L, Shulman R, Shulman G. Increased rate of gluconeogenesis in type II diabetes. A 13C nuclear magnetic resonance study. J Clin Invest 90: 1323–1327, 1992.PubMedCrossRefGoogle Scholar
  76. 76.
    Amer P, Einarsson K, Ewerth S, Livingston J. Altered action of glucagon on human liver in Type 2 (noninsulin-dependent) diabetes mellitus. Diabetologia 30: 323–326, 1987.CrossRefGoogle Scholar
  77. 77.
    Krahn D, Mackenzie T. Organic personality syndrome caused by insulin-related nocturnal hypoglycemia. Psychosomatics 25: 711–712, 1984.PubMedCrossRefGoogle Scholar
  78. 78.
    Silas J, Grant D, Maddocks J. Transient hemiparetic attacks due to unrecognised nocturnal hypoglycaemia. Brit Med J 282: 132–133, 1981.CrossRefGoogle Scholar
  79. 79.
    Chalmers J, Risk M, Kean D, Grant R, Ashworth B, Campbell I. Severe amnesia after hypoglycemia. Clinical, psychometric, and magnetic resonance imaging correlations. Diabetes Care 14: 922–925, 1991.PubMedCrossRefGoogle Scholar
  80. 80.
    Fisher B, Quin J, Rumley A, Lennie S, Small M, MacCuish A, Lowe G. Effects of acute insulin-induced hypoglycaemia on haemostasis, fibrinolysis and haemorheology in insulin-dependent diabetic patients and control subjects. Clinical Science 80: 525–531, 1991PubMedGoogle Scholar
  81. 81.
    Wredling R, Levander S, Adamson U, Lins P. Permanent neuropsychological impairment after recurrent episodes of severe hypoglycaemia in man. Diabetologia 33: 152–157, 1990.PubMedCrossRefGoogle Scholar
  82. 82.
    Patrick A, Campbell L Fatal hypoglycaemia in insulin-treated diabetes mellitus: clinical features and neuropathological changes. Diabetic Med 7: 349–354, 1990.PubMedCrossRefGoogle Scholar
  83. 83.
    Pladziewicz D, Nesto R. Hypoglycemia-induced silent myocardial ischemia. Am J Cardiol 63: 1531–1532, 1989.PubMedCrossRefGoogle Scholar
  84. 84.
    Duh E, Feinglos M. Hypoglycemia-induced angina pectoris in a patient with diabetes mellitus. Ann Intern Med 121: 945–946, 1994.PubMedCrossRefGoogle Scholar
  85. 85.
    Perros P, Frier B. The long-term sequelae of severe hypoglycemia on the brain in insulin-dependent diabetes mellitus. Horm Metab Res 29: 197–202, 1997.PubMedCrossRefGoogle Scholar
  86. 86.
    Kohner E, McLeod D, Marshall J. Complications of Diabetes, London, Edward Arnold, 1982.Google Scholar
  87. 87.
    Deary I, Crawford J, Hepburn D, Langan S, Blackmore L, Frier B. Severe hypoglycemia and intelligence in adult patients with insulin-treated diabetes. Diabetes 341–344, 1993.Google Scholar
  88. 88.
    Paz-Guevara A, Hsu T-H, White P. Juvenile diabetes mellitus after forty years. Diabetes 24: 559–565, 1975.PubMedCrossRefGoogle Scholar
  89. 89.
    Nabarro J, Mustaffa B, Morris D, Walport M, Kurtz A. Insulin deficient diabetes. Contrasts with other endocrine deficiencies. Diabetologia 16: 5–12, 1979.PubMedCrossRefGoogle Scholar
  90. 90.
    Seltzer H. Severe drug-induced hypoglycemia: a review. Comprehensive Therapy 5: 21–29, 1979.PubMedGoogle Scholar
  91. 91.
    Berger W, Caduff F, Pasquel M, Rump A. Die relative haufigkeit der schweren Sulfonylharnstoff-hypoglykamie in den letzten 25 Jahren in der Schweiz. Schwerz.Med.Wschr. 116: 145–151, 1986.Google Scholar
  92. 92.
    Mintz D, Finster J, Taylor A, Fefea A. Hormonal genesis of glucose intolerance following hypoglycemia. Am J Med 45: 187–197, 1968.PubMedCrossRefGoogle Scholar
  93. 93.
    Frier B, Corrall R, Ashby J, Baird J. Attenuation of the pancreatic beta-cell response to a meal following hypoglycemia in man. Diabetologia 18: 297–300, 1980.PubMedCrossRefGoogle Scholar
  94. 94.
    Attvall S, Fowelin J, von Schenck H, Smith U. Insulin resistance in type I (insulin-dependent) diabetes following hypoglycemia-evidence for the importance of B- adrenergic stimulation. Diabetologia 30: 691–697, 1987.PubMedCrossRefGoogle Scholar
  95. 95.
    Kollind M, Adamson U, Lins P. Insulin resistance following nocturnal hypoglycemia in insulin-dependent diabetes mellitus. Acta Endocrinol 116: 314–320, 1987.PubMedGoogle Scholar
  96. 96.
    Clore J, Brennan J, Gebhart S, Newsome H, Nestler J, Blackard W. Prolonged insulin resistance following insulin-induced hypoglycemia. Diabetologia 30: 851–858, 1987.PubMedGoogle Scholar
  97. 97.
    Gale E, Kurtz A, Tattersall R. In search of the Somogyi effect. Lancet 2:279–282, 1980.Google Scholar
  98. 98.
    Havlin C, Cryer P. Nocturnal hypoglycemia does not commonly result in major morning hyperglycemia in patients with diabetes mellitus. Diabetes Care 10: 141–147, 1987.PubMedCrossRefGoogle Scholar
  99. 99.
    Tordjman K, Havlin C, Levandoski L, White N, Santiago J, Cryer P. Failure of nocturnal hypoglycemia to cause fasting hyperglycemia in patients with insulin-dependent diabetes mellitus. NEngl J Med 31: 1552–1559, 1987.CrossRefGoogle Scholar
  100. 100.
    Gaston S. Outcomes of hypoglycemia treated by standardized protocol in a community hospital. Diabetes Educ 18: 491–494, 1992.PubMedCrossRefGoogle Scholar
  101. 101.
    Slama G, Traynard P, Desplanque N, Pudar H, Dhunputh I, Letanoux M, Bornet F, Tchobroutsky G. The search for an optimized treatment of hypoglycemia. Carbohydrates in tablets, solution, or gel for the correction of insulin reactions. Arch Intern Med 150: 589–593, 1990.PubMedCrossRefGoogle Scholar
  102. 102.
    Palatnick W, Meatherall R, Tenenbein M. Clinical spectrum of sulfonylurea overdose and experience with diazoxide therapy. Arch Intern Med 151: 1859–1862, 1991.PubMedCrossRefGoogle Scholar
  103. 103.
    Cryer P, Gerich J. Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus. N Engl J Med 313: 232–241, 1985.PubMedCrossRefGoogle Scholar
  104. 104.
    Bolli G. How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes. Diabetes Care 22 (Suppl 2): B43 - B52, 1999.PubMedGoogle Scholar
  105. 105.
    Boland E, Grey M, Oesterle A, Fredrickson L, Tamborlane W. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 22: 1779–1784, 1999.PubMedCrossRefGoogle Scholar
  106. 106.
    Bode B, Steed RD, Davidson P. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 19: 324–327, 1996.PubMedCrossRefGoogle Scholar
  107. 107.
    Brunelle R, Llewelyn J, Anderson J, Gale E, Koivisto V. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 21: 1726–1731, 1998.PubMedCrossRefGoogle Scholar
  108. 108.
    Pieber T, Eugene-Jolchine I, Derobert E, The European Study Group of HOE 901 in Type 1 Diabetes. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 23: 157–162, 2000.PubMedCrossRefGoogle Scholar
  109. 109.
    Dagogo-Jack S, Rattarason C, Cryer P. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation in IDDM. Diabetes 43: 1426–1434, 1994.PubMedCrossRefGoogle Scholar
  110. 110.
    Fritsche A, Stumvoll M, Haring H, Gerich J. Reversal of hypoglycemia unawareness in a long-term type 1 diabetic patient by improvement of beta-adrenergic sensitivity after prevention of hypoglycemia. J Clin Endocrinol Metab 85: 523–525, 2000.PubMedCrossRefGoogle Scholar
  111. 111.
    Fanelli C, Pampanelli S, Epifano L, Rambotti A, Vincenzo A, Modarelli F, Ciofetta M, Lepore M, Annibale B, Torlone E, Perriello G, DeFeo P, Santeusano F, Brunetti P, Bolli G. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 37: 1265–1276, 1994.PubMedCrossRefGoogle Scholar
  112. 112.
    Cranston I, Lomas J, Maran A, MacDonald I, Amiel S. Restoration of hypoglycemia unawareness in patients with long-duration insulin-dependent diabetes. Lancet 344: 283–287, 1994.PubMedCrossRefGoogle Scholar
  113. 113.
    Davis M, Mellman M, Friedman S, Chang C, Shamoon H. Recovery of epinephrire response but not hypoglycemic symptom threshold after intensive therapy in type 1 diabetes. Am J Med 97: 535–542, 1994.PubMedCrossRefGoogle Scholar
  114. 114.
    Fanelli C, Epifano L, Rambotti A, Pampanelli S, Di Vincenzo A, Modarelli F, Lepore M, Annibale B, Ciofetta M, Bottini P, Porcellati F, Scionti L, Santeusanio F, Brunetti P, Bolli G. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 42: 1683–1689, 1993.PubMedCrossRefGoogle Scholar
  115. 115.
    Kendall D, Teuscher A, Robertson R. Defective glucagon secretion during sustained hypoglycemia following successful islet allo-and autotransplantation in humans. Diabetes 46: 23–27, 1997.PubMedCrossRefGoogle Scholar
  116. 116.
    Meyer C, Hering B, Großmann R, Brandhorst H, Brandhorst D, Gerich J, Federlin K, Bretzel R. Improved glucose counterregulation and autonomic symptoms after intraportal islet transplants alone in patients with long-standing type I diabetes mellitus. Transplantation 66: 233–240, 1998.PubMedCrossRefGoogle Scholar
  117. 117.
    Federlin K, Pozza G. Indications for clinical islet transplantation today and in the foreseeable future-The diabetologist’s point of view. J Mol Med 77: 148–152, 1999.PubMedCrossRefGoogle Scholar
  118. 118.
    Bosi E, Piatti P, Secchi A, Monti L, Traeger J, Dubernard J, Pozza G. Response of glucagon and insulin secretion to insulin-induced hypoglycemia in diabetic patients after pancreatic transplantation. Diab Nutr Metab 1: 21–27, 1988.Google Scholar
  119. 119.
    Diem P, Redman J, Abid M, Moran A, Sutherland D, Halter J, Robertson R. Glucagon, catecholamine, and pancreatic polypeptide secretion in type I diabetic recipients of pancreas allografts. J Clin Invest 86: 2008–2013, 1990.PubMedCrossRefGoogle Scholar
  120. 120.
    Bolinder J, Wahrenberg H, Persson A, Linde B, Tyden G, Groth C, Ostman J. Effect of pancreas transplantation on glucose counterregulation in insulin-dependent diabetic patients prone to severe hypoglycaemia. J Int Med 230: 527–533, 1991.CrossRefGoogle Scholar
  121. 121.
    Bolinder J, Wahrenberg H, Linde B, Tyden G, Groth C, Ostman J. Improved glucose counterregulation after pancreas transplantation in diabetic patients with unawareness of hypoglycemia. Transplant Proc 23: 1667–1669, 1991.PubMedGoogle Scholar
  122. 122.
    Landgraf R, Nusser J, Riepl R, Fiedler F, Iimner W, Abendroth D, Land W. Metabolic and hormonal studies of Type 1 (insulin-dependent) diabetic patients after successful pancreas and kidney transplantation. Diabetologia 34 (Suppl 1): S61 - S67, 1991.PubMedCrossRefGoogle Scholar
  123. 123.
    Barrou Z, Seaquist E, Robertson R. Pancreas transplantation in diabetic humans normalizes hepatic glucose production during hypoglycemia. Diabetes 43: 661–666, 1994.PubMedCrossRefGoogle Scholar
  124. 124.
    Kendall D, Rooney D, Smets Y, Bolding L, Robertson R. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type 1 diabetes and autonomic neuropathy. Diabetes 46: 249–257, 1997.PubMedCrossRefGoogle Scholar
  125. 125.
    Luzi L, Battezzati A, Perseghin G, Bianchi E, Vergani S, Secchi A, La Rocca E, Staudacher C, Spotti D, Ferrari G, Di Carlo V, Pozza G. Lack of feedback inhibition of insulin secretion in denervated human pancreas. Diabetes 41: 1632–1639, 1992.PubMedCrossRefGoogle Scholar
  126. 126.
    Battezzati A, Luzi L, Perseghin G, Bianchi E, Spotti D, Secchi A, Vergani S, Di Carlo V, Pozza G. Persistence of counter-regulatory abnormalities in insulin-dependent diabetes mellitus after pancreas transplantation. Eur J Clin Invest 24: 751–758, 1994.PubMedCrossRefGoogle Scholar
  127. 127.
    Gupta V, Wahoff D, Rooney D, Poitout V, Sutherland D, Kendall D, Robertson R. The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined. Diabetes 46: 28–33, 1997.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Christian Meyer
  • Steven D. Wittlin
  • John E. Gerich

There are no affiliations available

Personalised recommendations